Fund Management Business
Arthurian Life Sciences Ltd (ALS) is a wholly-owned subsidiary of Arix Bioscience plc and operates as the regulated investment manager of the Group. ALS is also the Manager of The Wales Life Sciences Investment Fund (WLSIF) and is authorised and regulated by the Financial Conduct Authority.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Arix has a strategic agreement to provide to UCB reasonable access to its process of acquiring its Group Businesses, including participation in deal sourcing, deal screening and due diligence with a view to facilitating UCB’s investment in such Group Businesses in therapeutic areas including fields of immunology, neurology and bone, by establishing a joint advisory committee.